"Combination-oriented Molecular-Targeting Prevention" of cancer: A model involving the combination of TRAIL and a DR5 inducer

Environmental Health and Preventive Medicine

Volumn 15, Issue 4, 2010, Pages 203-210

  Yoshida, Tatsushi ^a   Horinaka, Mano ^a   Sakai, Toshiyuki ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Apoptosis; Cancer; Combination; DR5; Prevention; TRAIL

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; BUTYRIC ACID; CAROTENOID; CCAAT ENHANCER BINDING PROTEIN; DEATH RECEPTOR 4; DEATH RECEPTOR 5; FENRETINIDE; FLAVONOID; HISTONE DEACETYLASE INHIBITOR; LUTEOLIN; NORDIHYDROGUAIARETIC ACID; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; SULFORAPHANE; TRICHOSTATIN A; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; CELL CYCLE ARREST; CLINICAL TRIAL; COLON CANCER; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; DRUG TARGETING; FIBROSARCOMA; FOOD COMPOSITION; FOOD DRUG INTERACTION; FOOD INTAKE; GENE EXPRESSION REGULATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR MODEL; NONHUMAN; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; SKIN PAPILLOMA; STOMACH CANCER; TRANSCRIPTION REGULATION;

EID: 77956474946     PISSN: 1342078X     EISSN: 13474715     Source Type: Journal    
DOI: 10.1007/s12199-009-0128-3     Document Type: Review

References (72)

1. Sowa Y, Sakai T. Gene-regulating chemoprevention against cancer-as a model for molecular-targeting prevention of cancer (in Japanese). Nippon Eiseigaku Zasshi. 2003;58:267-74.
2. Matsuzaki Y, Sowa Y, Hirose T, Yokota T, Sakai T. Histone deacetylase inhibitors-promising agents for gene-regulating chemoprevention and molecular-targeting prevention of cancer. Environ Health Prev Med. 2003;8:157-60.
3. Matsuzaki Y, Sakai T. INK4 family-a promising target for gene-regulating chemoprevention and molecular-targeting prevention of cancer. Environ Health Prev Med. 2005;10:72-7.
4. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ash-kenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 1996;271:12687-90.
5. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999;5:157-63.
6. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 1999;104:155-62.
7. Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther. 2005;12:228-37.
8. Pan G, Ni J, Wei Y-F, Yu G-L, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science. 1997;277:815-8.
9. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 1997;277:818-21.
10. Screaton GR, Mongkolsapaya J, Xu X-N, Cowper AE, McMichael AJ, Bell JI. TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr Biol. 1997;7:693-6.
11. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J. 1997;16:5386-97.
12. Wu GS, Burns TF, McDonald ER 3rd, Jiang W, Meng R, Krantz ID, et al. KILLER/DR5 is a DNA damage-inducible p53-regu-lated death receptor gene. Nat Genet. 1997;17:141-3.
13. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 2003;10:66-75.
14. Takeda K, Stagg J, Yagita H, Okumura K, Smyth MJ. Targeting death-inducing receptors in cancer therapy. Oncogene. 2007; 26:3745-57.
15. Yamada H, Tada-Oikawa S, Uchida A, Kawanishi S. TRAIL causes cleavage of bid by caspase-8 and loss of mitochondrial membrane potential resulting in apoptosis in BJAB cells. Bio-chem Biophys Res Commun. 1999;265:130-3.
16. Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T, et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med. 2001;7:954-60.
17. Pukac L, Kanakaraj P, Humphreys R, Alderson R, Bloom M, Sung C, et al. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer. 2005;92:1430-41.
18. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer. 2005;5:876-85.
19. Grosse-Wilde A, Voloshanenko O, Bailey SL, Longton GM, Schaefer U, Csernok AI, et al. TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. J Clin Invest. 2008;118:100-10.
20. Finnberg N, Klein-Szanto AJ, El-Deiry WS. TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. J Clin Invest. 2008;118:111-23.
21. Shindoh N, Mori M, Terada Y, Oda K, Amino N, Kita A, et al. YM753, a novel histone deacetylase inhibitor, exhibits antitumor activity with selective, sustained accumulation of acetylated histones in tumors in the WiDr xenograft model. Int J Oncol. 2008;32:545-55.
22. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibi¬tors: molecular mechanisms of action. Oncogene. 2007;26:5541-52.
23. Sowa Y, Orita T, Minamikawa S, Nakano K, Mizuno T, Nomura H, et al. Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem Biophys Res Commun. 1997;241:142-50.
24. Nakano K, Mizuno T, Sowa Y, Orita T, Yoshino T, Okuyama Y, et al. Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line. J Biol Chem. 1997;272:22199-206.
25. Sowa Y, Orita T, Minamikawa-Hiranabe S, Mizuno T, Nomura H, Sakai T. Sp3, but not Sp1, mediates the transcriptional acti¬vation of the p21/WAF1/Cip1 gene promoter by histone deace-tylase inhibitor. Cancer Res. 1999;59:4266-70.
26. Sowa Y, Sakai T. Butyrate as a model for gene-regulating che-moprevention and chemotherapy. Biofactors. 2000;12:283-7.
27. INK4b in HDAC inhibitor-induced growth arrest. FEBS Lett. 2003; 554:347-50.
28. INK4d gene. FEBS Lett. 2004;574:171-5.
29. Yokota T, Matsuzaki Y, Miyazawa K, Zindy F, Roussel MF, Sakai T. Histone deacetylase inhibitors activate INK4d gene through Sp1 site in its promoter. Oncogene. 2004;23:5340-9.
30. Hirose T, Sowa Y, Takahashi S, Saito S, Yasuda C, Shindo N, et al. p53-Independent induction of Gadd45 by histone deace-tylase inhibitor: coordinate regulation by transcription factors Oct-1 and NF-Y. Oncogene. 2003;22:7762-73.
31. Nakata S, Yoshida T, Horinaka M, Shiraishi T, Wakada M, Sakai T. Histone deacetylase inhibitors upregulate death receptor 5/ TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene. 2004;23:6261-71.
32. Shukla S, Gupta S. Dietary agents in the chemoprevention of prostate cancer. Nutr Cancer. 2005;53:18-32.
33. Taghavi N, Yazdi I. Type of food and risk of oral cancer. Arch Iran Med. 2007;10:227-32.
34. Nishino H, Murakoshi M, Ii T, Takemura M, Kuchide M, Kanazawa M, et al. Carotenoids in cancer chemoprevention. Cancer Metastasis Rev. 2002;21:257-64.
35. Elangovan V, Sekar N, Govindasamy S. Chemopreventive potential of dietary bioflavonoids against 20-methylcholanthrene-induced tumorigenesis. Cancer Lett. 1994;87:107-13.
36. Ueda H, Yamazaki C, Yamazaki M. Inhibitory effect of Perilla leaf extract and luteolin on mouse skin tumor promotion. Biol Pharm Bull. 2003;26:560-3.
37. Matsukawa Y, Marui N, Sakai T, Satomi Y, Yoshida M, Mat-sumoto K, et al. Genistein arrests cell cycle progression at G2-M. Cancer Res. 1993;53:1328-31.
38. Ko WG, Kang TH, Lee SJ, Kim YC, Lee BH. Effects of luteolin on the inhibition of proliferation and induction of apoptosis in human myeloid leukaemia cells. Phytother Res. 2002;16:295-8.
39. Horinaka M, Yoshida T, Shiraishi T, Nakata S, Wakada M, Nakanishi R, et al. Luteolin induces apoptosis via death receptor 5 upregulation in human malignant tumor cells. Oncogene. 2005;24:7180-9.
40. Horinaka M, Yoshida T, Shiraishi T, Nakata S, Wakada M, Nakanishi R, et al. The combination of TRAIL and luteolin enhances apoptosis in human cervical cancer HeLa cells. Bio-chem Biophys Res Commun. 2005;333:833-8.
41. Horinaka M, Yoshida T, Shiraishi T, Nakata S, Wakada M, Sakai T. The dietary flavonoid apigenin sensitizes malignant tumor cells to tumor necrosis factor-related apoptosis-inducing ligand. Mol Cancer Ther. 2006;5:945-51.
42. Krinsky NI, Johnson EJ. Carotenoid actions and their relation to health and disease. Mol Aspects Med. 2005;26:459-516.
43. Nishino H, Tsushima M, Matsuno T, Tanaka Y, Okuzumi J, Murakoshi M, et al. Anti-neoplastic effect of halocynthiaxanthin, a metabolite of fucoxanthin. Anticancer Drugs. 1992;3:493-7.
44. Tsushima M, Maoka T, Katsuyama M, Kozuka M, Matsuno T, Tokuda H, et al. Inhibitory effect of natural carotenoids on Epstein-Barr virus activation activity of a tumor promoter in Raji cells. A screening study for anti-tumor promoters. Biol Pharm Bull. 1995;18:227-33.
45. Murakami A, Nakashima M, Koshiba T, Maoka T, Nishino H, Yano M, et al. Modifying effects of carotenoids on superoxide and nitric oxide generation from stimulated leukocytes. Cancer Lett. 2000;149:115-23.
46. Yoshida T, Maoka T, Das SK, Kanazawa K, Horinaka M, Wakada M, et al. Halocynthiaxanthin and peridinin sensitize colon cancer cell lines to tumor necrosis factor-related apoptosis-inducing ligand. Mol Cancer Res. 2007;5:615-25.
47. Fahey JW, Zhang Y, Talalay P. Broccoli sprouts: an exception¬ally rich source of inducers of enzymes that protect against chemical carcinogens. Proc Natl Acad Sci USA. 1997;94:10367-72.
48. Chung FL, Conaway CC, Rao CV, Reddy BS. Chemoprevention of colonic aberrant crypt foci in Fischer rats by sulforaphane and phenethyl isothiocyanate. Carcinogenesis. 2000;21:2287-91.
49. Fahey JW, Haristoy X, Dolan PM, Kensler TW, Scholtus I, Stephenson KK, et al. Sulforaphane inhibits extracellular, intra-cellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors. Proc Natl Acad Sci USA. 2002;99:7610-5.
50. Singh AV, Xiao D, Lew KL, Dhir R, Singh SV. Sulforaphane induces caspase-mediated apoptosis in cultured PC-3 human prostate cancer cells and retards growth of PC-3 xenografts in vivo. Carcinogenesis. 2004;25:83-90.
51. Jackson SJ, Singletary KW. Sulforaphane: a naturally occurring mammary carcinoma mitotic inhibitor, which disrupts tubulin polymerization. Carcinogenesis. 2004;25:219-27.
52. Matsui TA, Sowa Y, Yoshida T, Murata H, Horinaka M, Wakada M, et al. Sulforaphane enhances TRAIL-induced apoptosis through the induction of DR5 expression in human osteosarcoma cells. Carcinogenesis. 2006;27:1768-77.
53. Straus DS, Glass CK. Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med Res Rev. 2001;21:185-210.
54. 12,14-prostaglandin J2 activates the expres¬sion of p15INK4b gene, a cyclin-dependent kinase inhibitor. Int J Oncol. 2005;27:497-503.
55. 12,14-prostaglandin J2 induces death receptor 5 expression through mRNA stabilization independently of PPARc and potentiates TRAIL-induced apoptosis. Mol Cancer Ther. 2006;5:1827-35.
56. Hagmann W. Lipoxygenase in human tumor cells. Pathol Oncol Res. 1997;3:83-8.
57. Shureiqi I, Lippman SM. Lipoxygenase modulation to reverse carcinogenesis. Cancer Res. 2001;61:6307-12.
58. Yu A, Hashimura T, Nishio Y, Kanamaru H, Fukuzawa S, Yoshida O. Anti-promoting effect of nordihydroguaiaretic acid on N-butyl-N-(4-hydroxybutyl) nitrosamine and sodium saccha¬rin-induced rat urinary bladder carcinogenesis. Jpn J Cancer Res. 1992;83:944-8.
59. Tong WG, Ding XZ, Witt RC, Adrian TE. Lipoxygenase inhib¬itors attenuate growth of human pancreatic cancer xenografts and induce apoptosis through the mitochondrial pathway. Mol Cancer Ther. 2002;1:929-35.
60. Yoshida T, Shiraishi T, Horinaka M, Nakata S, Yasuda T, Goda AE, et al. Lipoxygenase inhibitors induce death receptor 5/ TRAIL-R2 expression and sensitize malignant tumor cells to TRAIL-induced apoptosis. Cancer Sci. 2007;98:1417-23.
61. Clifford JL, Menter DG, Wang M, Lotan R, Lippman SM. Retinoid receptor-dependent and-independent effects of N-(4-hydroxyphenyl)retinamide in F9 embryonal carcinoma cells. Cancer Res. 1999;59:14-8.
62. Lovat PE, Ranalli M, Bernassola F, Tilby M, Malcolm AJ, Pearson AD, et al. Synergistic induction of apoptosis of neuroblastoma by fenretinide or CD437 in combination with chemotherapeutic drugs. Int J Cancer. 2000;88:977-85.
63. Malone W, Perloff M, Crowell J, Sigman C, Higley H. Fenreti-nide: a prototype cancer prevention drug. Expert Opin Investig Drugs. 2003;12:1829-42.
64. Kouhara J, Yoshida T, Nakata S, Horinaka M, Wakada M, Ueda Y, et al. Fenretinide up-regulates DR5/TRAIL-R2 expression via the induction of the transcription factor CHOP and combined treatment with fenretinide and TRAIL induces synergistic apop-tosis in colon cancer cell lines. Int J Oncol. 2007;30:679-87.
65. Shiraishi T, Yoshida T, Nakata S, Horinaka M, Wakada M, Mizutani Y, et al. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells. Cancer Res. 2005;65:6364-70.
66. Yoshida T, Shiraishi T, Nakata S, Horinaka M, Wakada M, Mizutani Y, et al. Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homolo¬gous protein. Cancer Res. 2005;65:5662-7.
67. Goda AE, Yoshida T, Horinaka M, Yasuda T, Shiraishi T, Wakada M, et al. Mechanisms of enhancement of TRAIL tumoricidal activity against human cancer cells of different origin by dipyridamole. Oncogene. 2008;27:3435-45.
68. Yasuda T, Yoshida T, Goda AE, Horinaka M, Yano K, Shiraishi T, et al. Anti-gout agent allopurinol exerts cytotoxicity to human hormone-refractory prostate cancer cells in combination with TRAIL. Mol Cancer Res. 2008;6:1852-60.
69. Taniguchi T, Yoshida T, Horinaka M, Yasuda T, Goda AE, Konishi M, et al. Baicalein overcomes TRAIL resistance via two different cell specific pathways in cancer cells but not in normal cells. Cancer Res. 2008;68:8918-27.
70. Tecchio C, Huber V, Scapini P, Calzetti F, Margotto D, Todes-chini G, et al. IFNa-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells. Blood. 2004;103:3837-44.
71. Clarke N, Jimenez-Lara AM, Voltz E, Gronemeyer H. Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL. EMBO J. 2004;23:3051-60.
72. Ludwig AT, Moore JM, Luo Y, Chen X, Saltsgaver NA, O'Donnell MA, et al. Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guerin-induced antitumor activity. Cancer Res. 2004;64:3386-90.